No Data
No Data
Galapagos to Amend Gilead Deal; to Spin off Innovative Medicines Unit
6-K: Report of foreign private issuer (related to financial reporting)
Retail Investors Are Galapagos NV's (AMS:GLPG) Biggest Owners and Were Hit After Market Cap Dropped €74m
Express News | Galapagos NV-Granted Option to Exclusively License Uza-Cel for Global Development,Commercialization in Potential Future Solid Tumor Cancer Indications
Express News | Galapagos NV: Galapagos Has Been Granted an Option to Exclusively License Uza-Cel for Global Development and Commercialization in Head & Neck Cancer
Express News | Galapagos NV: Adaptimmune to Receive Additional Development and Sales Milestone Payments of up to a Maximum of $465 Mln